ArticleLeukemia & lymphoma2020
Cost-effectiveness of polatuzumab vedotin in relapsed or refractory diffuse large B-cell lymphoma.
Kishan K Patel et al.PubMed ↗Publisher ↗
No numbers read from the abstract.
6 papers cite it
this paperpooled itcites it